Neil E. Kay, MD, a professor of medicine at the Mayo Clinic, discusses the challenges that arise when treating a patient with relapsed chronic lymphocytic leukemia (CLL). Most times, responses in this setting are short lived.
Neil E. Kay, MD, a professor of medicine at the Mayo Clinic, discusses the challenges that arise when treating a patient with relapsed chronic lymphocytic leukemia (CLL). Historically, responses in this setting have been short lived.
Newer drugs such as ibrutinib (Imbruvica), idelalisib (Zydelig), rituximab (Rituxan), and venetoclax (Venclexta) have been approved by the FDA for relapsed/refractory CLL. Kay notes there is less emphasis on prognostic factors to determine whether a patient would be able to receive these agents. However, adverse prognostic factors mean less to a physician when treating a patient with one of these agents, Kay says.
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More